Key result
Angiotensin-converting enzyme inhibition increased blood levels of bradykinin, but not kallidin, peptides, indicating differential regulation of the kinin peptide systems.
Why the study?
Does angiotensin-converting enzyme inhibition alter blood levels of bradykinin and kallidin peptides in humans?
Population
Humans
Authors
Loading...
May guide investigation of kinin-mediated ACE inhibitor effects; hypothesis-generating and should not change practice.
Observational
Does angiotensin-converting enzyme inhibition alter blood levels of bradykinin and kallidin peptides in humans?
This study demonstrates differential regulation of the bradykinin and kallidin peptide systems, showing that blood levels of bradykinin are more responsive to ACE inhibition than kallidin.
Duncan et al. (2000) reported an observational. Angiotensin-converting enzyme inhibition was evaluated on Blood levels of bradykinin and kallidin peptides. Angiotensin-converting enzyme inhibition increased blood levels of bradykinin, but not kallidin, peptides, indicating differential regulation of the kinin peptide systems.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: